Global CRISPR Technologies Patent Landscape Report 2024

Patent Landscape Report Coverage

The Global CRISPR Technologies Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for CRISPR Technologies include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation associated with CRISPR Technologies. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within CRISPR Technologies.

Key Inclusions:

• Patent Valuation Analysis

An evaluation and competitive benchmarking of key members of unique patent families are covered in the analysis of CRISPR technologies. The important parameters have been taken into consideration including IP document, year of application, number of citations, time to expiry, and jurisdiction associated with CRISPR technologies.

• Analysis of Patent Applications

A comprehensive summary of several patent applications which were filed across different jurisdictions for CRISPR technologies, and their relative value are covered. The analysis will cover the capital in terms of innovation and innovation type.

• Analysis of Granted Patents

Detailed analysis of the granted patents across different jurisdictions for CRISPR technologies and their relative value in the IP are covered in the final report.

CRISPR Technologies Patent Outlook

• Growing usage of CRISPR technology to develop genetically modified crops with improved traits such as disease resistance, drought tolerance, and enhanced nutritional profiles, appealing to both producers and consumers.
• The growing adoption of CRISPR is likely to drive the global CRISPR technology market. For example, CRISPR technology can help edit a gene by transforming the DNA from a hazardous variation to a healthy variant. This could help prevent or treat a genetic condition. In June 2021, QIAGEN announced QIAprep CRISPR Kit and CRISPR Q-Primer Solutions, which allow researchers to assess altered genetic material with unprecedented speed and efficiency to identify how their interventions have changed the function of the DNA sequence.
• Technological improvements in CRISPR technology are projected to fuel the worldwide CRISPR technology market. For example, in December 2020, scientists at UC Berkeley and Gladstone Institutes developed a new CRISPR-based COVID-19 diagnostic test that, with the help of a smartphone camera, can provide a positive or negative result in 15 to 30 minutes, allowing doctors to monitor the progression of a COVID-19 infection.

What are CRISPR Technologies?

CRISPR, or "Clustered Regularly Interspaced Short Palindromic Repeats," is a groundbreaking gene-editing technology that enables scientists to precisely manipulate DNA within live creatures. CRISPR technology uses RNA molecules and the Cas9 protein to target and edit certain genes. It has grown in prominence due to its efficiency, precision, and versatility in a wide range of applications, including biomedical research, gene therapy, agriculture, and functional genomics. The CRISPR technology industry has grown dramatically, driven by advances in genome editing, increased biotechnology investments, and a growing need for precise gene-editing tools across a wide range of businesses.

CRISPR technology is increasingly being used in industrial contexts for bio-manufacturing, including the manufacture of biofuels and industrial enzymes, leading to an increased number of patent applications. Its market share in various applications is growing, solidifying its position as a prominent category. CRISPR-based solutions improve efficiency in industrial operations, which contributes to the growth of this application category. However, regulatory concerns and public perceptions provide barriers to wider adoption in specific industrial uses. Biological research, including functional genomics and basic research, is a key application area for CRISPR technology. This area is characterized by continuous innovation, making it a significant contributor to patent progress. CRISPR's versatility in investigating gene functions and biological systems ensures its continued use in scientific applications.

CRISPR Technologies Industry Growth Drivers

Rising Investments in Healthcare Companies and Advancement in Genome Editing is Expected to Boost the Patent Industry Growth

The CRISPR technology patent industry has grown significantly as genome editing advances. Continuous research has resulted in the development of CRISPR procedures, making them more accurate and adaptable. This progress has not only increased usage across a wide range of applications but has also fueled the overall expansion of the CRISPR technology market. The tremendous expansion in biotechnology and healthcare spending from both the private and public sectors has been a significant driver of the CRISPR technology patent industry. These financial infusions have provided critical support for the research, development, and commercialization of CRISPR-based goods and therapies, accelerating market penetration. Moreover, the increasing prevalence of genetic abnormalities has emerged as a major motivator for the use of CRISPR technology, notably in medicine. As the prevalence of genetic diseases rises, so does the demand for precise and effective gene-editing techniques, underlining CRISPR-based therapies' considerable potential in treating genetic disorders.

Increasing Development of New Vaccines and Treatment of Genetic Diseases is Expected to Propel CRISPR Technologies Patent Industry Demand

The discovery of new vaccinations and treatments for genetic illnesses utilizing CRISPR technology represents a game-changing prospect in the realm of healthcare. CRISPR's precise gene editing capabilities have enormous potential for treating infectious diseases and resolving the genetic origins of many maladies. This possibility not only promises new ways to prevent and treat diseases but also transforms the way we approach healthcare treatments. Editas Medicine is undertaking a phase 1/2 experiment for severe sickle cell disease (SCD) using a CRISPR method with Cas12a protein instead of the well-known Cas9 protein. Furthermore, Vertex Pharmaceuticals and CRISPR Therapeutics are collaborating on Beta-thalassemia.

CRISPR Technologies Patent Segmentation

CRISPR Technologies Patent Segmentation Analysis

The breakup based on type includes products and services. The product segment (CRISPR kits and enzymes) dominates the market. Enzymes and CRISPR kits are critical for developing disease models for scientific research. Scientists can reproduce ill conditions in cells or organisms by introducing genetic defects associated with diseases. This strategy is beneficial for determining the causes of diseases and evaluating potential therapies.

CRISPR Technologies Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for CRISPR technology patents, having around 34,900+ patents. The presence of big companies, well-established healthcare infrastructure, and advanced research and development activities contributes to the regional patent landscape significantly.

Patent Profile of Key Companies

Among the players within CRISPR technologies patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the CRISPR technologies field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Wuhan Bowo Innovation Biotechnology Co. Ltd.

Wuhan Bowo Innovation Biotechnology Co., Ltd. is a biotechnology company based in Wuhan, China, specializing in gene editing technologies, particularly CRISPR/Cas9 and related applications. The company focuses on developing innovative solutions in areas such as genetic engineering, molecular biology, and therapeutic applications.

Monsanto Technology LLC

Monsanto Technology LLC, a subsidiary of Bayer AG, is a leading agricultural biotechnology company known for i...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other companies include Excision Biotherapeutics Inc., Pioneer Hi Bred Int, and Crispr Therapeutics Ag, among others.

Reasons to Purchase this Report

The CRISPR technologies patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and makes it understandable which companies have important patents in this field of CRISPR technologies.
• Innovation Insights: The patent analysis reveals new innovations and technologies in CRISPR Technologies.
• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry within the CRISPR technologies patent landscape.
• Risk Assessment: In technology-intensive fields such as CRISPR technologies, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.